Laevoroc Oncology

Hunenberg, Switzerland Founded: 2019 • Age: 7 yrs
Therapeutics for pancreatic, ovarian, breast, and brain cancers are developed.

About Laevoroc Oncology

Laevoroc Oncology is a Healthcare company based in Hunenberg (Switzerland) founded in 2019 by Davide Guggi. Therapeutics for pancreatic, ovarian, breast, and brain cancers are developed. Laevoroc Oncology has raised $1.1 million across 1 funding round. Laevoroc Oncology offers products and services including LR09, LR06, and LR02. Its focus areas include Life Sciences, Neurology, Drugs and Brain Cancer. Its legal entity is Laevoroc Oncology AG.

Company details

Developer of therapeutics for cancer. The drug candidates include LR 06 an oral gemcitabine prodrug for pancreatic, ovarian, and breast cancers, LR09 guides the immune system to eradicate relapsed leukemia after allogeneic stem cell transplantation, and LR02 is a central nervous system ATR inhibitor for treating brain cancer.

  • Headquarters Hunenberg, Switzerland
  • Founders Davide Guggi
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website laevoroc.com
  • Social LinkedIn YouTube
  • Legal Name Laevoroc Oncology Ag
Key Metrics
  • Total Equity Funding
    $1.1M (USD)

    in 1 rounds

  • Latest Funding Round
    $1.1M (USD), Seed

    May 2021

Products & Services of Laevoroc Oncology

Laevoroc Oncology offers a comprehensive portfolio of products and services, including LR09, LR06, and LR02.

LR09
Immunotherapy Drug

Inhibitor targeting relapsed leukemia after stem cell transplantation

LR06
Chemotherapy Drug

Oral prodrug for maintenance therapy in various cancers

LR02
Oncology Drug

Inhibitor for brain cancer treatment with CNS penetration

Apps and channels of Laevoroc Oncology

its YouTube channel LAEVOROC Oncology has 0026 subscribers.

LAEVOROC Oncology
YouTube 0026 subscribers
Open channel

Funding Insights of Laevoroc Oncology

Laevoroc Oncology has successfully raised a total of $1.1M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.1 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.1M
  • Total Rounds 1
  • Last Round Seed β€” $1.1M
  • First Round $1.1M

    (May 2021)

All 1 funding rounds of Laevoroc Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2021$1.1MSeed––
–

People of Laevoroc Oncology

4 people are tracked at Laevoroc Oncology (4 in leadership).

NameRoleGroup
Davide Guggi
Co-FounderLeadership
Thomas Mehrling
Founder-ceo At LaevorocLeadership
Jessica Kourniakti, DPhil
Chief Operating OfficerLeadership
Shanta Bantia
Co-founder - CSO At Laevoroc ImmunologyLeadership
Premium access

Complete people profiles for Laevoroc Oncology

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Laevoroc Oncology

2 dated milestones of Laevoroc Oncology across 2 years, from founding to its latest funding, stage changes and deals.

  1. Founded Laevoroc Oncology is founded.
  2. Funding First funding round of $1.1M.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Laevoroc Oncology

Premium access

Complete news archive for Laevoroc Oncology

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Laevoroc Oncology

Laevoroc Oncology was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Laevoroc Oncology is headquartered in Hunenberg, Switzerland. It is registered at Hunenberg, Zug, Switzerland.

Laevoroc Oncology is a funded company, having raised a total of $1.1M across 1 funding round to date. The company's 1st funding round was a Seed of $1.1M, raised on May 2021.

Developer of therapeutics for cancer. The drug candidates include LR 06 an oral gemcitabine prodrug for pancreatic, ovarian, and breast cancers, LR09 guides the immune system to eradicate relapsed leukemia after allogeneic stem cell transplantation, and LR02 is a central nervous system ATR inhibitor for treating brain cancer.

Laevoroc Oncology offers LR09, LR06, and LR02.

Laevoroc Oncology operates through Laevoroc Oncology Ag.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available